Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

Journal of Experimental Medicine

Volumn 190, Issue 11, 1999, Pages 1669-1678

  Thurner, Beatrice ^a   Haendle, Ina ^a   Röder, Claudia ^a   Dieckmann, Detlef ^a   Keikavoussi, Petra ^b   Jonuleit, Helmut ^c   Bender, Armin ^a   Maczek, Christian ^a   Schreiner, Doris ^a   Von Den Driesch, Peter ^a   Bröcker, Eva B ^b   Steinman, Ralph M ^d   Enk, Alexander ^c   Kämpgen, Eckhart ^b   Schuler, Gerold ^a,e  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ROCKEFELLER UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Active immunotherapy; Cytotoxic T lymphocytes; Dendritic cells; Melanoma; Vaccination

Indexed keywords

TETANUS TOXOID; TUBERCULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; METASTASIS; MONOCYTE; PRIORITY JOURNAL; SKIN METASTASIS; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; T-LYMPHOCYTES, CYTOTOXIC; TETANUS TOXOID; TUBERCULIN;

EID: 0033405438     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.11.1669     Document Type: Article

References (36)

1. Schreiber, H. 1999. Tumor Immunology. In Fundamental Immunology. W.E. Paul, editor. Lippincott-Raven Publishers, Philadelphia. 1237-1270.
2. Van den Eynde, B.J., and P. van der Bruggen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9:684-693.
3. Schuler, G., and R.M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 8:1183-1187.
4. Pardoll, D.M. 1998. Cancer vaccines. Nat. Med. 4(Suppl.): 525-531.
5. Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641-1650.
6. Rosenberg, S.A. 1998. New opportunities for the development of cancer immunotherapies. Cancer J. Sci. Am. 4(Suppl.):S1-4.
7. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 393:245-252.
8. Lotze, M.T., H. Farhood, C.W. Wilson, and W.J. Storkus. 1999. Dendritic cell therapy of cancer and HIV infection. In Dendritic Cells: Biology and Clinical Applications. M.T. Lotze and A. Thomson, editors. Academic Press, San Diego, CA. 459-485.
9. Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
10. Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:371-380.
11. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysare-pulsed dendritic cells. Nat. Med. 4:328-332.
12. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kämpgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods. 196:137-151.
13. Thurner, B., C. Röder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Keikavoussi, E. Kämpgen, A. Bender, and G. Schuler. 1999. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods. 223:1-15.
14. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:219-230.
15. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921-930.
16. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J. Immunol. Methods. 203:141-152.
17. Romero, P., J.C. Cerottini, and G.A. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol. Med. Today. 4:305-312.
18. Chaux, P., V. Vantomme, P. Coulie, T. Boon, and P. van der Bruggen. 1998. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer. 77:538-542.
19. Zhou, L.J., and T.F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154:3821-3835.
20. Lanzavecchia, A. 1998. Immunology. Licence to kill. Nature. 393:413-414.
21. Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A.H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135-3142.
22. Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. Cerundolo, D.F. Nixon, et al. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104:173-180.
23. + T cells resulting in a failure to lyse tumor cells. Blood. 93:1634-1642.
24. Enk, A.H., H. Jonuleit, J. Saloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer. 73:309-316.
25. Sato, T., P. McCue, K. Masuoka, S. Salwen, E.C. Lattime, M.J. Mastrangelo, and D. Berd. 1996. Interleukin 10 production by human melanoma. Clin. Cancer Res. 2:1383-1390.
26. Dummer, W., J.C. Becker, A. Schwaaf, M. Leverkus, T. Moll, E.B. Bröcker. 1995. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 5:67-68.
27. Keikavoussi, P., C. Carstens, C. Scheicher, F. Koch, W. Fries, E.B. Brocker, N. Koch, and E. Kämpgen. 1999. Full maturation of human monocyte derived dendritic cells results in stable expression of MHC class I molecules. Arch. Dermatol. Res. 291:110. (Abstr.)
28. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature. 388:782-787.
29. Dieu, M.C., B. Vanbervliet, A. Vicari, J.M. Bridon, E. Oldham, S. Ait-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373-386.
30. Balch, C.M., A.N. Houghton, A.J. Sober, and S. Soong. 1998. Cutaneous Melanoma. 3rd ed. Quality Medical Publishing Corporation, St. Louis, MO. 596.
31. Kamanabrou, D., C. Straub, M. Heinsch, C. Lee, and A. Lippold. 1999. Sequential biochemotherapy of INF-α/IL-2, cisplatin (CDDP), dacarbacine (DTIC) and carmustine (BCNU). Result of a monocenter phase II study in 109 patients with advanced metastatic malignant melanoma (MMM). Proc. Am. Soc. Clin. Oncol. 18:2044a. (Abstr.)
32. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263-1272.
33. Wong, B.R., R. Josien, S.Y. Lee, B. Sauter, H.L. Li, R.M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186:2075-2080.
34. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965-1971.
35. Chaux, P., V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, R. Luiten, A.M. Eggermont, T. Boon, and P. van der Bruggen. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med. 189:767-778.
36. Shimizu, K., R.C. Fields, M. Giedlin, and J.J. Mule. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA. 96:2268-2273.